|

Anti-OX40 Antibody PF-04518600 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PF-04518600

Pipeline

Phase 2: 1

Top Sponsors

  • Laura Huppert, MD, BA1

Indications

  • Stage IIIC Breast Cancer1
  • Stage IIIB Breast Cancer1
  • Stage IIIA Breast Cancer1
  • Stage III Breast Cancer1
  • Stage IV Breast Cancer1

Birmingham, Alabama1 trial

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

O'Neal Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.